Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
Zealand Pharma announced participation in the H.C. Wainwright BIOCONNECT 2022 Conference on January 10, 2022. Members of its senior management team will present at 7:00 a.m. EST. A pre-recorded webcast will be accessible at the time of the presentation on the company's investor relations page. Zealand Pharma specializes in peptide-based medicines and has more than 10 drug candidates in clinical development, with two already on the market and three in late-stage development. The company has collaborations with Boehringer Ingelheim and AstraZeneca.
- Participation in the prestigious H.C. Wainwright BIOCONNECT 2022 Conference enhances visibility.
- The company has over 10 drug candidates in clinical development, indicating a robust pipeline.
- Collaboration with Boehringer Ingelheim and AstraZeneca could lead to expanded market opportunities.
- None.
Company announcement – No. 1 / 2022
Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
Copenhagen, DK and Boston, MA, U.S. January 3, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate in the H.C. Wainwright BIOCONNECT 2022 Conference:
H.C. Wainwright BIOCONNECT 2022 Conference
Date: Monday, January 10, 2022
Presentation: 7:00 a.m. EST / 12:00 p.m. GMT / 1:00 p.m. CET
A pre-recorded webcast of the presentation will be available at the time of the presentation on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Maeve Conneighton |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
When is Zealand Pharma's presentation at the H.C. Wainwright BIOCONNECT 2022 Conference?
How many drug candidates does Zealand Pharma have in clinical development?
What are Zealand Pharma's collaborations?
What is Zealand Pharma's focus?
